Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 95,800 shares of the stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $10.45, for a total transaction of $1,001,110.00. Following the transaction, the insider now owns 2,155,930 shares in the company, valued at $22,529,468.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of NASDAQ CMPI opened at $10.47 on Wednesday. Checkmate Pharmaceuticals, Inc. has a 52 week low of $2.00 and a 52 week high of $10.48. The firm’s fifty day moving average is $6.12 and its 200 day moving average is $4.19. The company has a market cap of $230.76 million, a price-to-earnings ratio of -3.59 and a beta of -4.86.
Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share (EPS) for the quarter. As a group, equities analysts predict that Checkmate Pharmaceuticals, Inc. will post -3.14 EPS for the current year.
A number of equities research analysts have recently issued reports on the stock. BTIG Research cut shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 20th. Zacks Investment Research raised Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 3rd.
About Checkmate Pharmaceuticals (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
- Get a free copy of the StockNews.com research report on Checkmate Pharmaceuticals (CMPI)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.